Could an HIV drug tame MS by targeting a common virus?

NCT ID NCT05957913

ENROLLING_BY_INVITATION Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This study tests whether Truvada, an antiviral drug used for HIV prevention, can reduce levels of Epstein-Barr virus (EBV) in people with multiple sclerosis (MS). EBV is linked to MS, and the hope is that lowering the virus might help control the disease. The trial will enroll 50 adults with MS who have evidence of past EBV infection and will monitor virus levels in saliva and blood, along with safety and fatigue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Truvada (tenofovir/emtricitabine)
What this could lead to: If successful, this could point toward a new way to manage multiple sclerosis by targeting the Epstein-Barr virus, potentially reducing disease activity.
What could go wrong: This is a small, early-stage trial focused on virus levels, not on improving MS symptoms directly. The drug is not approved for MS, and side effects or lack of effect on the disease are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.